 |
| Researchers work in a laboratory at the headquarters of EDGC in Songdo, Incheon. Courtesy of EDGC |
By Ko Dong-hwan
 |
EDGC said, Dec. 28, that the two South Korean firms will research how to "infuse genome sequencing technologies with immunology-tumor pipelines" and "genetically categorize cancer patients based on next-genome-sequencing (NGS) to clinically study the immunology-tumor pipelines."
EDGC's chief technology officer Lee Sung-hoon said the latest co-operation will bring his company "one step closer to perfectly treating cancer patients in customized and precise ways." He said the joint research will help not just treat but also diagnose cancers more effectively.
Eutilex CEO Choi Soo-young expected its partnership with the Songdo-based company in Incheon to improve his firm's anticancer immunotherapy technologies to treat more patients.
EDGC said the partnership is particularly valuable in that immunology-tumor treatment can be improved thanks to NGS's precision diagnosis.
Eutilex, based in Seoul's Geumcheon District, recently applied to the U.S. Food and Drug Administration for phase 1 and 2 clinical studies for the cancer immunotherapy drug "EU101."
![[INTERVIEW] South Korea needs to make decision on sending lethal aid to Ukraine : CNAS CEO](https://img.koreatimes.co.kr/upload/thumbnailV2/a2180e54d7664819812514cc3d605dd5.jpg/dims/resize/178/optimize)
![[INTERVIEW] Foreign-born entertainers seek to revolutionize local industry](https://img.koreatimes.co.kr/upload/thumbnailV2/4a6b2bd3d23044d699dee3c5bb956863.jpg/dims/resize/178/optimize)
